THE POWER OF BIG PHARMA ON NAFTA NEGOTIATIONS

In his first State of the Union address, Donald Trump again reiterated his campaign promise to bring down drug costs. But a year into his presidency, he’s done nothing of the sort. And if U.S. negotiators and powerful corporate lobbyists have their way, the new North American Free Trade Agreement (NAFTA) will change in ways that would keep drug prices high and out of reach for people in Canada, the U.S., Mexico and beyond.
The Trudeau government keeps saying that governments must be allowed to regulate in the public interest. Instead of bowing to Big Pharma, Canadian negotiators now have the opportunity to advance a key Canadian interest.